Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Burkhard Timmler"'
Autor:
Alexander Birkmann, Susanne Bonsmann, Dirk Kropeit, Tamara Pfaff, Manickam Rangaraju, Melanie Sumner, Burkhard Timmler, Holger Zimmermann, Helmut Buschmann, Helga Ruebsamen-Schaeff
Publikováno v:
Journal of medicinal chemistry. 65(20)
When the nucleoside analogue acyclovir was introduced in the early 1980s, it presented a game-changing treatment modality for herpes simplex virus infections. Since then, work has been ongoing to improve the weaknesses that have now been identified:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69be1720a16217550c44fc70babd502
https://pubmed.ncbi.nlm.nih.gov/36202389
https://pubmed.ncbi.nlm.nih.gov/36202389
Autor:
Hans Peter Stobernack, Stephen K. Tyring, Amalia Magaret, Helga Ruebsamen-Schaeff, Anna Wald, Burkhard Timmler, Lawrence Corey, Stacy Selke, Alexander Birkmann, Kenneth H. Fife, Meei Li Huang, Christine Johnston, Terri Warren, Holger Zimmermann
Publikováno v:
JAMA. 316(23)
Importance Current therapy of herpes infections relies on nucleoside analogues. Pritelivir is a well-tolerated novel herpes simplex virus (HSV) helicase-primase inhibitor that reduced genital shedding and lesions. Objective To compare the efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21c36d0727ce883c2f7b4551204d77fb
https://pubmed.ncbi.nlm.nih.gov/28125749
https://pubmed.ncbi.nlm.nih.gov/28125749
Autor:
Burkhard Timmler, Susanne Stoelben, Lawrence Corey, Joachim Ossig, Christopher M. Rubino, Helga Ruebsamen-Schaeff, David A. Swan, Murad Melhem, Alexander Birkmann, Anna Wald, Joshua T. Schiffer, Scott A. Van Wart, Holger Zimmermann, Amalia Magaret
Publikováno v:
Science translational medicine. 8(324)
Pharmacokinetic and pharmacodynamic models estimate the potency of antiviral agents but do not capture viral and immunologic factors that drive the natural dynamics of infection. We designed a mathematical model that synthesizes pharmacokinetics, pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::678a05c59f7b5675f50dc317e58d9078
https://pubmed.ncbi.nlm.nih.gov/26843190
https://pubmed.ncbi.nlm.nih.gov/26843190
Autor:
Thomas Goldner, Craig A. Magaret, Susanne Stoelben, Burkhard Timmler, Alexander Birkmann, Lawrence Corey, Holger Zimmermann, Anna Wald, Kurt Diem, Jia Jin Kee, Paul T. Edlefsen, Helga Ruebsamen-Schaeff, Meei Li Huang, Terri Warren
Publikováno v:
The Journal of Infectious Diseases
Pritelivir (also known as BAY 57–1293 and AIC316) belongs to a new class of antiviral compounds, the helicase-primase inhibitors (HPIs), that prevent the de novo synthesis of virus DNA through inhibition of the helicase-primase complex [1]. Functio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::127735b538d367e57cab8a7735251865
https://pubmed.ncbi.nlm.nih.gov/27056950
https://pubmed.ncbi.nlm.nih.gov/27056950
Autor:
Lawrence Galitz, Hans Peter Stobernack, Alexander Birkmann, Stacy Selke, Helga Ruebsamen-Schaeff, Terri Warren, John D. Kriesel, Amalia Magaret, Meei Li Huang, Anna Wald, Susanne Stoelben, Lawrence Corey, Stephen K. Tyring, Kenneth H. Fife, Burkhard Timmler, Christine Johnston
Publikováno v:
The New England journal of medicine. 370(3)
Background Pritelivir, an inhibitor of the viral helicase–primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. We tested the efficacy and safety of pritelivir in otherwise healthy perso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837bba111dd1485b4effaeae68409ba2
https://pubmed.ncbi.nlm.nih.gov/24758629
https://pubmed.ncbi.nlm.nih.gov/24758629
Autor:
Meei-Li Huang, Burkhard Timmler, Susanne Stoelben, Lawrence Corey, Stephen K. Tyring, Alexander Birkmann, Christine Johnston, Terri Warren, Anna Wald, Helga Ruebsamen-Schaeff
Publikováno v:
Sexually Transmitted Infections. 87:A78-A79
Background Current treatments for HSV infection are imperfect, do not completely abrogate viral shedding or transmission, and do not interrupt HSV-2—HIV interactions. AIC316 is a helicase-primase inhibitor, a new class of anti-HSV compounds that ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d56755ee625ed31a215382ee3784917
https://doi.org/10.1136/sextrans-2011-050109.127
https://doi.org/10.1136/sextrans-2011-050109.127